PTC Therapeutics (PTCT) said Friday that its marketing authorization application for Sephience for the treatment of phenylketonuria has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use.
The CHMP opinion recommends a label that includes all ages and disease severities, the company said, adding it expects the European Commission to take a decision in about two months.
The company said launch planning in Europe is ongoing, with Germany as a priority market.
Sephience, or sepiapterin, is also under review in the US for phenylketonuria, an inherited metabolic disease that affects the brain, PTC said.
Price: 48.78, Change: -0.77, Percent Change: -1.55
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。